Emergent BioSolutions Inc. (EBS) — Stock Score Summary

Emergent BioSolutions Inc. (EBS) has a MoatMap StockRank of 69/100 based on Quality (57/100), Value (62/100), and Momentum (34/100) factor scores. The current signal is BUY. Emergent BioSolutions is a highly distressed biopharma company with a history of severe operational and regulatory failures. We do not invest in broken business models hoping for a macro rescue, strictly adhering to our quality filters.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on providing specialized products that address public health threats, including medical countermeasures and vaccines. The company develops, manufactures, and commercializes products for anthrax, smallpox, and opioid overdose, serving government agencies and commercial markets. Its unique focus on biodefense and public health readiness establishes a niche market leadership with long-term government contracts.

Key Financial Metrics

Price$7.95
Market Cap$474M
P/E (Forward)2.82
Price/Book0.84
Return on Equity-1.6%
Return on Invested Capital12.0%
Debt/Equity111.76
Gross Margin47.5%
Operating Margin6.8%
Revenue Growth-29.7%
Free Cash Flow$256M

Emergent BioSolutions Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Emergent BioSolutions Inc.’s (EBS) StockRank?
MoatMap’s StockRank for Emergent BioSolutions Inc. (EBS) is 69/100, with a Buy signal. It is a composite of Quality (57), Value (62), and Momentum (34) factor ranks across MoatMap’s 19,000+ stock universe.
Does Emergent BioSolutions Inc. have an economic moat?
Emergent BioSolutions Inc. (EBS) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Emergent BioSolutions Inc. a buy, hold, or sell?
MoatMap’s current signal for Emergent BioSolutions Inc. (EBS) is Buy, based on a StockRank of 69/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Emergent BioSolutions Inc. in?
Emergent BioSolutions Inc. (EBS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksEBS deep dive reportAI ChampionsHow we score stocksSense-check another stock